1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-2247, NCT00442533
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2-55-52030-726, NCT00353496
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCSF-04458, NCT00227617
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CTCT 06-11, NCT00493883
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 07-325, NCT00576680
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-04-C-0273, NCI-6332, DELCATH-G990039, NCT00096083
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: END0002, 97273, END0002, NCT00398320, NCT00398320
|
|
8.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E4206, E4206, NCT00427349
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and over
Sponsor: NCI
Protocol IDs: MDA-2006-0077, MDACC 2006-0077, 7650, NCT00454363
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-14888, 105001a, GA6181079, NCT00434109
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CO07203, NIH R21CA117117-01A2, NCT00501540
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PTK787/ZK222584, LSU IRB-6355, NCT00590343
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 07-162, NCT00610129
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CPTK787/ZK222584, NCT00627198
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP13-0710, NCT00781911
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CC#084511, NCT00843531
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: CAP/TEM for Neuroendocrine CA, AAAB3348, NCT00869050
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SU-03272009-2039, END0008, NCT00947167
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 25
Sponsor: NCI
Protocol IDs: UIHC-200008086, NCI-V02-1710, NCT00049023, 200008086
|
|
20.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: N05-10564, NCT00314925
|
|
21.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-07-C-0047, NCI-P6880, NCT00436735
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-03740, NCT00580320
|
|
23.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC0414, MC0414, NCT00655655
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-087, NCT00804336
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-094, NCT00942682
|
